First natural, herbal medicine for overweight patients registered in Germany and available throughout the EU

Diapharm is licensing the new registration of a plant-based medicine with seaweed powder for overweight individuals, both nationally and for the whole of Europe.

The German Federal Institute for Drugs and Medical Devices (BfArM) has granted pharmaceutical consultancy Diapharm the first traditional herbal registration for a medicinal product complementing a weight loss diet for overweight patients. The seaweed powder with 130 mg of bladderwrack (Fucus vesiculosus) is available in Germany in the form of a plant-based film-coated tablet for the first time. The recommended dosage is one film-coated tablet with water twice a day, two hours before meals.

“Demand for natural plant-based remedies with confirmed indications is constantly increasing,” says Nicole Sibbing, Director of Diapharm (www.diapharm.com): “The ‘green’ shift in consumer preferences is directly related to social changes”, she adds. Bladderwrack is a brown algae that is native to the North Atlantic and contains iodine. The recommended daily dose contains up to 210 micrograms of iodine.

The Fucus preparation is the first traditional herbal medicine with an approved indication as an adjuvant to reduced calorie diet to help weight loss in overweight adults, after serious conditions have been excluded by a medical doctor (“zur Ergänzung einer kalorienreduzierten Gewichtsreduktionsdiät bei übergewichtigen Erwachsenen, nachdem durch einen Arzt schwerwiegende Grunderkrankungen ausgeschlossen wurden”) to be made available to users in Germany.

Seaweed-based medicines containing bladderwrack have been used for weight loss in the United Kingdom and France for decades. “Herbal medications are often a regional tradition,” explains Dr Rainer Kolkmann from Diapharm: “Something that has been established in one EU country can be virtually unknown in other countries” he notes. “We consistently take the opportunity to identify such medications and their potential, register them Europe-wide and introduce them to the market.” The company has already managed the registration and approval of more than 500 such medications in 23 countries.

Diapharm does not distribute medicines itself. Instead, it licences the registration, including the dossier, to pharmaceutical companies with their own OTC brands, both nationally and for the whole of Europe. For more information visit: www.diapharm.com/fucus/

(approx. 2,300 characters)

Share:  
News

 

  1. Contact us!
  2. Service hotline: +49 251 609350 
    +43 1 5321606 
    +31 133029063 
    +86 21 6057 7019 

  3. E-Mail: info@diapharm.com

  4. Salutation*

This website uses cookies

We use cookies to improve the user experience. By continuing to use this website, you consent to the use of cookies.